Review Article

Prostaglandin E\textsubscript{2} and the Suppression of Phagocyte Innate Immune Responses in Different Organs

Alexandra Medeiros,\textsuperscript{1} Camila Peres-Buzalaf,\textsuperscript{2} Felipe Fortino Verdan,\textsuperscript{1} and C. Henrique Serezani\textsuperscript{3}

\textsuperscript{1}Department of Biological Sciences, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, 14801-902 São Paulo, SP, Brazil
\textsuperscript{2}Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo (USP), Av Octávio Pinheiro Brisolla 9-75, Bauru, 17012-901 São Paulo, SP, Brazil
\textsuperscript{3}Department of Microbiology and Immunology, Indiana University School of Medicine, 950 West Walnut Street, Indianapolis, IN 46202, USA

Correspondence should be addressed to C. Henrique Serezani, chserez@usp.br

Received 15 February 2012; Revised 19 April 2012; Accepted 3 May 2012

Academic Editor: Ruxana Sadikot

Copyright © 2012 Alexandra Medeiros et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The local and systemic production of prostaglandin E\textsubscript{2} (PGE\textsubscript{2}) and its actions in phagocytes lead to immunosuppressive conditions. PGE\textsubscript{2} is produced at high levels during inflammation, and its suppressive effects are caused by the ligation of the E prostanoid receptors EP\textsubscript{2} and EP\textsubscript{4}, which results in the production of cyclic AMP. However, PGE\textsubscript{2} also exhibits immunostimulatory properties due to binding to EP\textsubscript{3}, which results in decreased cAMP levels. The various guanine nucleotide-binding proteins (G proteins) that are coupled to the different EP receptors account for the pleiotropic roles of PGE\textsubscript{2} in different disease states. Here, we discuss the production of PGE\textsubscript{2} and the actions of this prostanoid in phagocytes from different tissues, the relative contribution of PGE\textsubscript{2} to the modulation of innate immune responses, and the novel therapeutic opportunities that can be used to control inflammatory responses.

1. General Considerations

Prostaglandins (PGs) are lipid mediators derived from arachidonic acid (AA) metabolism via the activation of the cyclooxygenase (COX) pathway, that regulates inflammation, immune response, hematopoiesis, tissue injury and repair, and bone resorption. PGs are found in most tissues and organs, and the variety of effects that they can elicit reflects the presence of specific PG receptors in many cell types. Upon cell activation by microbial products, cytokines, and opsonins, cytosolic phospholipase A\textsubscript{2} (PLA\textsubscript{2}) is activated and recruited to hydrolase plasma cell phospholipid. Once it is released from the membrane, AA is rapidly converted into PGs by cells expressing prostaglandin H synthase (COX). At least two COX isofoms exist, the constitutive (COX-1) and inducible (COX-2) isofoms. COX-1 is expressed in many cell types distributed throughout the body, whereas COX-2 expression is highly restricted under basal conditions and upregulated during inflammation in different cell types [1] (see Figure 1). COX proteins are the major targets of nonsteroidal anti-inflammatory drugs (NSAIDs).

COX-2 is transcriptionally regulated by mediators that act through phosphatidylinositol 3-kinase (PI3K), extracellular signal-regulated kinase1/2 (ERK1/2), and p38, and the activation of COX-2 culminates in the activation of the transcription factors, nuclear factor kappa B (NF\textsubscript{k}B), activator protein (AP-1) and the cAMP response element-binding (CREB) [2, 3]. Therefore, COX-2 activity is induced by a variety of proinflammatory cytokines and growth factors and by one of its products, PGE\textsubscript{2}. Conversely, COX-2 expression is inhibited by glucocorticoids and interleukin (IL)-4. Both COX-1 and COX-2 are present in the active state in the endoplasmic reticulum and the nuclear envelope. These enzymes convert AA to the unstable endoperoxide
Although PGE2 is commonly considered to be a potent proinflammatory mediator [8], its role as a mediator of anti-inflammatory responses is now being studied [9, 10]. The anti-inflammatory response opposes the host inflammatory response, which potentially limits collateral damage to neighboring cells and tissues and aids in the resolution of inflammation after the pathogens are contained [11]. This dual effect depends on the cell type, the tissue compartment, the state of cellular activation, and the particular expression of the signaling-EP receptors. The existence of four subtypes of receptors that signal differently and can be expressed in different combinations in a single cell explains the multiplicity of biological responses that are elicited by PGE2 and how these responses may differ among cells and tissues. This paper reviews the recent knowledge regarding PGE2 synthesis and its modulatory effect on innate immune responses in different tissues.

2. Lung

The synthesis of PGE2 occurs in several different cellular types within the airways, such as epithelial cells, fibroblasts, vascular endothelial cells, and leukocytes [12]. The leukocytes that can synthesize PGE2 include the alveolar macrophages (AMs), neutrophils, follicular dendritic cells, and T cells. The relative capacity of these cells to produce PGE2 is shown in Table 1. The AMs represent a major source of PGE2 during microbial infection [13], whereas alveolar epithelial cells and pulmonary fibroblasts also represent an important source of PGE2 in the lungs [14]. High levels of PGE2 are produced in AMs following the lipopolysaccharide (LPS)-and granulocyte/macrophage colony-stimulating factor (GM-CSF)-dependent expression of the inducible form of COX-2 [15]. Several mediators and signal transduction pathways are involved in the modulation of the synthesis and release of PGE2 by these cells. The inhibition of endogenous rat AM-producing transforming growth factor (TGF)-β enhances PGE2 synthesis, while the expression of LPS-induced COX-2 and PGE2, which are released by human AMs, is upregulated following the inhibition of PI3K activity [3]. AMs also produce increased PGE2 after bone marrow transplantation [16]. Although neutrophils are considered to be the main producers of leukotriene B4 (LTB4) (5-lipoxygenase-derived lipid mediator), few studies have attempted to evaluate the ability of lung neutrophils to produce prostanoids. In fact, the majority of studies is focused on the peritoneal and peripheral blood-derived neutrophils [17]. One of these studies demonstrated that lung PMNs (but not AMs) from mice that received bone marrow transplants synthesized pronounced levels of PGE2 when compared with cells from control mice [16]. In general, the in vitro synthesis of the cytokine-induced PGE2 by neutrophils involves the activation and novel synthesis of COX [18]. In addition, while PGE2 synthesis is well documented in human monocyte-derived immature dendritic cells (DCs) [19], no studies to date have demonstrated the particular capacity of lung DCs to produce this mediator.
PGE2 produced in the lungs elicits a wide variety of effects [1]. The effects vary from the induction of tissue repair and pulmonary vascular remodeling [20] to the regulation of immune inflammatory responses [21].

AMs are the primary lung cells that are involved in the protection of the alveolar-blood interface and serve as the front line of cellular defense against respiratory pathogens [22] in both murine and human cells. AMs express all four types of EP receptors [23] and contribute greatly to the amount of PGE2 produced in infected lungs [13] (Table 1). Monick and collaborators have demonstrated that LPS induces COX-2 expression and PGE2 release in human AMs [3, 24].

The immunomodulatory effects of PGE2 are largely caused by its ability to increase intracellular cAMP through the stimulatory Gαs-coupled EP receptors EP2 and EP4 [25]. Increases in intracellular cAMP levels are transduced into cellular responses mediated by its effectors, cAMP-dependent protein kinase A (PKA), and the exchange protein directly activated by cAMP-1 (Epac) [26]. In phagocytes, the effects of PGE2 are usually anti-inflammatory since PGE2 has been demonstrated to inhibit the production of proinflammatory molecules and increase the secretion of anti-inflammatory cytokines, such as IL-10 [27]. In human AMs, PGE2 potently inhibited LPS-induced tumor necrosis factor (TNF)-α through the activation of the EP2 and EP4 receptors [28]. The downmodulation of LPS-induced TNF-α by PGE2 in rat AMs is dependent on cAMP signaling-dependent PKA activation since the selective PKA activating cAMP analog 6-Bnz-cAMP, but not the Epac-1 activating analog 8-pCPT-2-O-Me-cAMP, inhibits its production [29].

EP2 signaling is also involved in the enhancement of LPS-induced nitric oxide (NO) by the activation of PKA rather than Epac-1 [30]. Exogenous PGE2 can potentiate the synthesis of LPS-mediated IL-6 and IL-10 in rat AMs via AKAP10-(A-kinase anchoring protein-10-) mediated PKA signaling, while the suppression of TNF-α occurs via AKAP-8-anchored PKA-RII (PKA regulatory subunit type II) [30].

PGE2 has also been shown to inhibit AM FcR-mediated phagocytosis by activating the EP2 receptor, judged by the mimicked effect of the selective EP2 agonist butaprost [23] or a specific Epac-1 agonist (8-pCPT-2'-O-Me-cAMP) [32]. Moreover, PGE2 inhibits rat AM microbicidal activity and this effect was restored after treatment with indomethacin, EP2, and EP4 antagonists [31]. The role of EP3 receptor activation-driven AMs was also studied in the context of anti-inflammatory cytokines, such as IL-10 [27]. In human AMs, PGE2 potently inhibited LPS-induced tumor necrosis factor (TNF)-α through the activation of the EP2 and EP4 receptors [28].

The immunomodulatory effects of PGE2 are largely caused by its ability to increase intracellular cAMP through the stimulatory Gαs-coupled EP receptors EP2 and EP4 [25]. Increases in intracellular cAMP levels are transduced into cellular responses mediated by its effectors, cAMP-dependent protein kinase A (PKA), and the exchange protein directly activated by cAMP-1 (Epac) [26]. In phagocytes, the effects of PGE2 are usually anti-inflammatory since PGE2 has been demonstrated to inhibit the production of proinflammatory molecules and increase the secretion of anti-inflammatory cytokines, such as IL-10 [27]. In human AMs, PGE2 potently inhibited LPS-induced tumor necrosis factor (TNF)-α through the activation of the EP2 and EP4 receptors [28].

The immunomodulatory effects of PGE2 are largely caused by its ability to increase intracellular cAMP through the stimulatory Gαs-coupled EP receptors EP2 and EP4 [25]. Increases in intracellular cAMP levels are transduced into cellular responses mediated by its effectors, cAMP-dependent protein kinase A (PKA), and the exchange protein directly activated by cAMP-1 (Epac) [26]. In phagocytes, the effects of PGE2 are usually anti-inflammatory since PGE2 has been demonstrated to inhibit the production of proinflammatory molecules and increase the secretion of anti-inflammatory cytokines, such as IL-10 [27]. In human AMs, PGE2 potently inhibited LPS-induced tumor necrosis factor (TNF)-α through the activation of the EP2 and EP4 receptors [28].

The immunomodulatory effects of PGE2 are largely caused by its ability to increase intracellular cAMP through the stimulatory Gαs-coupled EP receptors EP2 and EP4 [25]. Increases in intracellular cAMP levels are transduced into cellular responses mediated by its effectors, cAMP-dependent protein kinase A (PKA), and the exchange protein directly activated by cAMP-1 (Epac) [26]. In phagocytes, the effects of PGE2 are usually anti-inflammatory since PGE2 has been demonstrated to inhibit the production of proinflammatory molecules and increase the secretion of anti-inflammatory cytokines, such as IL-10 [27]. In human AMs, PGE2 potently inhibited LPS-induced tumor necrosis factor (TNF)-α through the activation of the EP2 and EP4 receptors [28]. The downmodulation of LPS-induced TNF-α by PGE2 in rat AMs is dependent on cAMP signaling-dependent PKA activation since the selective PKA activating cAMP analog 6-Bnz-cAMP, but not the Epac-1 activating analog 8-pCPT-2-O-Me-cAMP, inhibits its production [29].

EP2 signaling is also involved in the enhancement of LPS-induced nitric oxide (NO) by the activation of PKA rather than Epac-1 [30]. Exogenous PGE2 can potentiate the synthesis of LPS-mediated IL-6 and IL-10 in rat AMs via AKAP10-(A-kinase anchoring protein-10-) mediated PKA signaling, while the suppression of TNF-α occurs via AKAP-8-anchored PKA-RII (PKA regulatory subunit type II) [30].

PGE2 has also been shown to inhibit AM FcR-mediated phagocytosis by activating the EP2 receptor, judged by the mimicked effect of the selective EP2 agonist butaprost [23] or a specific Epac-1 agonist (8-pCPT-2'-O-Me-cAMP) [32]. Moreover, PGE2 inhibits rat AM microbicidal activity and this effect was restored after treatment with indomethacin, EP2, and EP4 antagonists [31]. The role of EP3 receptor activation-driven AMs was also studied in the context of anti-inflammatory cytokines, such as IL-10 [27]. In human AMs, PGE2 potently inhibited LPS-induced tumor necrosis factor (TNF)-α through the activation of the EP2 and EP4 receptors [28]. The downmodulation of LPS-induced TNF-α by PGE2 in rat AMs is dependent on cAMP signaling-dependent PKA activation since the selective PKA activating cAMP analog 6-Bnz-cAMP, but not the Epac-1 activating analog 8-pCPT-2-O-Me-cAMP, inhibits its production [29].

EP2 signaling is also involved in the enhancement of LPS-induced nitric oxide (NO) by the activation of PKA rather than Epac-1 [30]. Exogenous PGE2 can potentiate the synthesis of LPS-mediated IL-6 and IL-10 in rat AMs via AKAP10-(A-kinase anchoring protein-10-) mediated PKA signaling, while the suppression of TNF-α occurs via AKAP-8-anchored PKA-RII (PKA regulatory subunit type II) [30].
Table 1: Prostaglandin E2 Synthesis and Receptor Expression in Leukocytes from different organs.

| Type of compartment | Type of cells      | Relative synthetic capacity | EP1 | EP2 | EP3 | EP4 |
|---------------------|-------------------|----------------------------|-----|-----|-----|-----|
| Lung                | Neutrophils       | −                          | +   | +   | +   | +   |
|                     | Alveolar macrophages | + +                        | −   | +   | +   | +   |
|                     | Dendritic cells   | + *                        | −   | +   | +   | +   |
| Spleen              | Neutrophils       | −                          | ND  | ND  | ND  | ND  |
|                     | Macrophages       | + *                        | ND  | ND  | ND  | ND  |
|                     | Dendritic cells   | +                         | ND  | ND  | ND  | ND  |
| Bone                | BMDM-derived      | + + +                      | +   | +   | +   | +   |
|                     | Osteoclasts       | +                         | +   | +   | +   | +   |

Relative synthetic capacity is expressed by the number of plus (+) signs; a minus sign (−) characterizes no or a negligible synthetic capacity. Receptor expression is classified as positive (+), negative (−), minimal (±), or not determined (ND). *Synthesis of PGE2 is relatively low in unstimulated conditions but is upregulated upon stimulation. **Receptor expression is upregulated during inflammatory stimulus.

pulmonary infection. Although the Gαi-coupled EP3 was thought to oppose the Gαi-coupled EP2 and EP1 receptors, EP1−/− mice were protected from bacterial induced death, which corroborates the increased ability of AMs to phagocytose and kills Streptococcus pneumoniae [33]. Through EP2, PGE2 was also involved in the mediation of the immunosuppressive response characterized by increased IL-10 synthesis and the impairment of neutrophil recruitment to the lungs during the ingestion of apoptotic cells (efferocytosis) by phagocytes [10]. As a suppressive mediator, PGE2 inhibits AA release and LTB4 synthesis in rat AMs by a mechanism independent of PLA2 [34].

Human and mouse lung DCs are localized in the airway epithelium, lung parenchyma, visceral pleura, and bronchoalveolar lavage fluid (BALF) [35]. DCs exposed to PGE2 exhibit a decreased capability to secrete proinflammatory cytokines [36]. They are in contact with many other cells in the lungs such as the airway epithelium, type II alveolar epithelial cells, AMs, pulmonary interstitial macrophages, (myo)fibroblasts, bronchus-associated lymphoid tissue (BALT) lymphocytes, nonadrenergic, noncholinergic (NANC) nerve endings, capillary endothelium, and mast cells. Although the particularly contribution of lung DC as producer of PGE2 is still unknown, there are several studies using bone-marrow-derived DCs (BM-DCs) showing that their immunomodulatory function is highly regulated by mediators including PGE2, potentially produced by neighboring cells in the lungs. BM-DCs exposed to PGE2 present decreased ability to secrete proinflammatory cytokines [36]. The importance of lung DC modulation by PGE2 is highlighted considering DC as the mediator cell of the adaptive immune response and the lungs as an important local tissue for airway microbial defenses [37].

Lung PMNs are the primary cells recruited to the lungs during acute lung injury [38]. LPS is an important inducer of the inflammatory response by its activation of Toll-like receptor 4 (TLR4). After binding to TLR4, LPS triggers the synthesis of chemoattractants that induce PMN migration at sites of inflammation, such as the lung [39]. The overproduced PGE2 by lung PMNs from bone marrow transplantation mice is involved to the decreased ability of PMN to kill Pseudomonas aeruginosa, an effect restored by the PG inhibition with indomethacin [16]. However, evaluation of EP signaling in the PGE2-mediated impaired host defense by lung PMMs is much less appreciated.

Due to the low yield of murine alveolar macrophages, one plausible alternative to study PGE2 synthesis/actions is the use of alveolar macrophage cell lines. However, a very limited number of studies have been done to identify the profile of PGE2 synthesis and actions in this cell line. Here, we are summarizing some of the key findings regarding the expression of COX mRNA and protein in MH-S murine alveolar macrophages. MH-S is a murine alveolar macrophage cell line transformed by SV40 obtained from Balb/c mice and displays several properties of primary AM, such phagocytic capacity and expression of Mac-1 antigen, major histocompatibility complex class II, the CR3 receptor, and the Fc receptor Mbwuike and Herscowitz, 1989 to [40]. LPS-stimulated MH-S cell line promotes robust increment of COX-2 and large amounts of PGE2 (Joo et al., 2005 to [41]; Chen et al., 2007 to [42]). Luteolin, a flavonoid that exhibits anti-inflammatory properties, is shown to inhibit COX-2 gene expression and PGE2, IL-6, TNF-α, and iNOS production in LPS-activated MH-S cells by decreasing NF-κB and AP-1 activation Chen et al., 2007 to [42]. In this context, LPS or overexpression of IKKβ is reported to activate NF-κB signaling and COX-2 expression, which was impaired after ectopic expression of hepatitis C virus in MH-S cells Joo et al., 2005 to [41]. However, so far there are no reports regarding EP receptors expression profile and the relative role of individual receptor in MH-S cells.

3. Spleen

Splenic macrophages, DCs, and lymphocytes contribute to PGE2 synthesis in the spleen [43]. In splenic tissues, mPGES-1 accounts for the majority of basal (COX1-dependent) PGE2 synthesis, and the in vivo mPGES-1 deletion abolished LPS-inducible PGE2 synthesis [44]. Normal splenic macrophages produce low levels of PGE2 when compared with bone-marrow-derived macrophages (BMDM; Table 1).
AMs, and peritoneal macrophages [45]. However, high levels of this mediator are produced by splenic macrophages in chronic inflammatory conditions, such as mycobacterial infection [46]. It has been shown that the formation of PGE2-producing splenic macrophages is dependent on the radiosensitive bone marrow cells [47]; the precursors migrate from the bone marrow cells to the spleen to become mature cells [48]. Splenic DCs appear phenotypically immature and mature after microbial stimuli [37]. The phenotype seems to be determined by other suppressive mediators, including NO, TGF-β, 1α, 25-dihydroxyvitamin D3 (vitamin D) and PGE2 produced by antigen-presenting cells (APCs) such as macrophages and DCs [49]. To date, no reports have described EP expression in splenic DCs; most studies are focused on bone-marrow-derived DCs (BM-DCs) [50]. These cells express all four EP receptors [51] that can induce different effects, including DC generation, migration, and maturation [52].

PGE2-producing macrophages that are induced from mycobacterial stimuli interact closely with splenic lymphocytes to induce a shift from the Th1 to Th2 immune responses in a PGH2 synthase-dependent manner [53]. This shift is based on the suppressive effect of the synthesis of Th1 cytokines, such as IL-1, IL-12, and interferon (IFN)-γ, but it does not affect Th2 cytokines [54]. The downmodulation of TNF-α synthesis by PGE2 in in vitro-derived BM-DCs occurs through EP2- and EP4-induced signal transduction events [55]. It has also been shown that this signaling can upregulate IL-23 synthesis and downmodulate APC-produced IL-12 [56], which favors the expansion of IL-17-producing Th17 cells [57].

4. Bone

PGE2 produced in the bone is primarily derived from osteoblasts, cells responsible for bone formation [58]. As shown in Table 1, mouse BMDMs, osteoclast precursors, and mature osteoclasts differently express EP receptors. BMDMs express the EP1, EP2, EP3β, and EP4 receptors, while mature osteoclasts only express the EP1 receptor [59]. It was demonstrated that PGE2 can stimulate cAMP levels in BMDMs but does not affect cAMP in mature osteoclasts; this result demonstrates that functional EP2 and EP4 receptors are inhibited in osteoclasts during its differentiation [59].

Osteoclasts are bone-resorbing multinucleated cells derived from the monocyte-macrophage lineage [60]. The differentiation and activation of osteoclasts are tightly regulated by osteoblasts through the release of receptor activator of NF-κB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) [61], which are required for the differentiation of osteoclast progenitors into mature osteoclasts [62]. RANKL activation induces COX-2 expression in immature osteoclast by utilizing a Rac1-dependent NK-κB activation pathway; that results in PGE2 synthesis and contributes to accelerated osteoclast differentiation [63].

In bone, PGE2 is known to be an important local factor in the regulation of bone formation [64] and resorption [65]. PGE2 acts in precursors and mature osteoclasts to regulate their function. PGE2 can directly inhibit the bone-resorbing activity of osteoclasts. This inhibitory effect was dependent on an increase in intracellular cAMP caused by activator of adenyly cyclase (forskolin) and mimicked by the EP2 and EP4 agonists (butaprost and AE-604). In calvaria culture from EP4 knockout mice, PGE2 presented an impaired role in promoting bone resorption, whereas EP3 agonist slightly restored bone resorption and EP4 agonist did not [66].

5. Central Nervous System (CNS)

Although the immunoprivileged status of the CNS is well known, similar to any other organ, it is connected and engaged with the immune system to maintain tissue homeostasis. An excessive inflammatory status can promote several types of brain damage, which include ischemia and neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease [67].

The CNS typically contains low prostanoid levels. Specifically, PGE2, PGD2, and PGF2α are associated with inflammatory responses [68]. Oddly, the COX-1 and COX-2 enzymes are both constitutively expressed in the CNS (in neurons, astrocytes, microglia and endothelia) [69], and a putative COX-3 enzyme, which is a splice variant of COX-1 that is denoted as COX-1b, is described in rodent and human neural tissues [70–72]. The PGE2 levels in the CNS are enhanced during various neurological diseases, such as multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease [68].

Importantly, the proinflammatory stimuli that lead to brain injury further enhance COX-2 expression and therefore enhance PGE2 synthesis. All three PGES isoforms are found in the CNS tissues, and the expression levels vary according to the cell type [73]. An elegant study demonstrated that brain PGE2 synthesis is orchestrated by COX-1/COX-2/membrane-associated cPGES (cPGES-m) and by nuclear/perinuclear COX-2/mPGES-1/cPGES [74].

Because few studies have described DCs and neutrophils in the CNS, we will focus primarily on the microglia functions. It is noteworthy that although there is a close relationship between the peripheral macrophages and microglia, all of the knowledge concerning the peripheral cells cannot simply be extended to microglia cells that are inserted in a unique environment.

Initially, astrocytes were reported to be the major source of prostanooids within the CNS [75], but later studies have demonstrated that microglial cells can release higher levels of PGE2, PGD2, and TXB2 than astrocytes [76]. Similar to peripheral macrophages, COX-2 is the main enzyme expressed by microglia after activation [77]. LPS induces high levels of PGE2 synthesis by upregulating COX-2 and mPGES-1 expression [76, 78]. Additionally, activation of microglia by TLR can be modulated by further PGE2 synthesis. Although factors such as TGF-β [79], TNF-α [80], norepinephrine [81], adenosine, and PGE2 [82], can act as COX-2 positive regulators, other factors, such as IFN-γ [83], IL-10 [79], NO [83], and lipocortin [84] are negative regulators of COX-2 expression and activation. Interestingly,
PGE\(_2\) synthesis is rapidly augmented when microglia are treated with phosphatidylserine (PS) liposomes in a manner that is dependent on the COX-1/mPGES-2 axis [85].

From the moment that PGE\(_2\) is released, it acts in close proximity to its production site in an autocrine or paracrine manner. In general, PGE\(_2\) acts as a suppressive mediator of the microglia. In the CNS, PGE\(_2\) primarily causes enhanced levels of cAMP [80], which further suggests a role for EP\(_2\) and EP\(_4\) in the mediation of CNS inflammation. Supporting its suppressive functions, studies of TLR4-mediated microglial activation have shown that PGE\(_2\) can inhibit the production of TNF-\(\alpha\) [86] and IL-12 [87], IL-18 [88], the expression of the B7-2 (CD86) costimulatory molecules [89], the enhancement of IL-10 and IL-6 production, and the expression of inducible nitric oxide synthase (iNOS). Additionally, a recent study has associated PGE\(_2\) with decreased microbicidal activity by microglial cells in meningitis [90].

In addition to its inflammatory roles, PGE\(_2\) is related to several central functions, such as fever (thermogenesis), the neuroendocrine axis, food intake, and behavior during sickness. Circulating IL-1\(\beta\) acts at the blood-brain barrier (BBB) to induce COX-2 expression and PGE\(_2\) synthesis, and PGE\(_2\) subsequently diffuses into the brain parenchyma to perform its actions [91]. Recent studies have revealed that central COX-2 inhibition did not abrogate fever induction or the increases in plasma corticosterones and anorexia, which suggests that other sources of PGE\(_2\), such as COX-2-independent peripherally synthesized PGE\(_2\) or COX-1-dependent centrally produced PGE\(_2\) [92], are involved. Interestingly, PGE\(_2\) production in the spinal cord is elevated by peripheral inflammation through COX-2 and mPGES-1 induction, which is correlated with peripheral edema potentiation, enhanced neuron hyperexcitability, and hyperalgesia [93]. Moreover, COX-2-dependent PGE\(_2\) is an important signaling mediator for synaptic modification [94].

The role of PGE\(_2\) in the brain remains controversial, and its differential effects depend on its specific receptor [95]. Because the expression and timing of the EP receptors vary according to the cell type and neuronal stimuli, the specific role of each EP receptor depends on its specific context (for an extensive review, see [96]). The EP\(_3\) receptor is likely not associated with inflammatory roles, while the EP\(_2\) and EP\(_4\) receptors appear to have opposing activities [96]. Although the EP\(_2\) receptor is related to a proinflammatory neurotoxic effect in activated microglia [97], the EP\(_4\) receptor has an anti-inflammatory, neuroprotective role [98]. These contradictory effects reflect the differential expression and timing of the EP receptors.

Consistent with the myriad activities of PGE\(_2\) and the dependence on the expression of specific EP receptors in different cell types, studies that investigate the roles of PGE\(_2\) in the CNS should be addressed carefully. The inflammatory effects of PGE\(_2\) are related to its dual neuroprotective and neurotoxic roles, and unless the PGE\(_2\) paradoxical effects are finely tuned, neurodegenerative diseases could occur. A full understanding of the roles of PGE\(_2\) and the dynamics of EP receptors in the CNS requires the study of the restrained areas of the CNS and the endogenous PGE\(_2\) functions relative to the different cell types and receptors that are involved.

6. Reproductive Tract

Uterine macrophages are an important source of PGs for uterine activity [99]. They are known to be potent agonists that promote contractile activity in the uterus, and either PGs or its precursor treatments initiate preterm labor throughout gestation. Therefore, LPS-induced uterine activation may be due to increased levels of proinflammatory cytokine and PGE\(_2\). Furthermore, exogenously added PGE\(_2\) analogs can reduce the innate immune defenses within the reproductive tract. Slama et al. provided a good example of the role of PGE2 in inhibiting innate immune response. They injected a PGE\(_2\) analog into the maternal cervix of cows for 1 wk following calf delivery and observed an increased purulent uterine secretions, increased frequency and severity of bacterial contamination of the uterus, and reduced levels of antibodies in uterine secretions. Pharmacological PGE\(_2\) administration facilitated the establishment of chlamydial infections of the murine female reproductive tract [100]. We have shown that the intrauterine administration of misoprostol in rats infected with Clostridium sordellii further enhanced the bacterial numbers in the uterine tract and was followed by decreased animal survival. This effect was associated with the inhibition of TNF-\(\alpha\) and defensin secretion by decidual macrophages and uterine epithelial cells [101]. Although little is known about the potential of misoprostol to suppress the reproductive tract’s innate immunity, a study reported an increase in the rate of infections when misoprostol was administered orally, and the rate increased with intravaginal administration [102]. This may help to explain the connection between medical abortion and clostridial endometritis in contrast to infections that are caused by more commonly encountered pathogens.

7. Peritoneal Macrophages

Peritoneal macrophages are extensively used as a model to investigate macrophage function. This cell type is a standard model used to identify inflammatory responses, cellular metabolism, and apoptosis. Resident peritoneal macrophages exhibit low responsiveness to inflammatory stimuli relative to inflammatory peritoneal macrophages that are recruited by inflammatory stimuli, such as thioglycolate, peptone or glycogen. Resident peritoneal macrophages express mainly EP\(_4\) but not EP\(_2\) mRNA at basal levels. In the presence of LPS, the expression of EP\(_4\) mRNA is downregulated to levels that are lower than in nonstimulated macrophages, and the expression of EP\(_2\) mRNA is transiently increased after 3 h of stimulation [103].

Peritoneal macrophages have a greater capacity for PGE\(_2\) synthesis than macrophages from different organs, such as alveolar macrophages or spleen macrophages. These cells have higher levels of cytotoxic and membrane COX-1 expression in activated cells, which are similar to the levels of COX-2 expression after LPS treatment [104].
The effect of PGE₂ in the inhibition of inflammatory cytokines, such as TNF-α, IL-1β, and IL-6, was initially demonstrated in peritoneal macrophages upon TLR4 activation [105]. However, recent studies described that the effects of PGE₂ are due to the production of IL-10 [106]. However, the suppressive effect of PGE₂ on IL-6 production is controversial and seems to be dependent on the inflammatory stimulus used. In addition to the modulation of cytokines, exogenous PGE₂ can also modulate the expression of the cell surface receptors of peritoneal macrophages. The addition of different concentrations of PGE₂ induces an increase in CD14 on the surface of peritoneal macrophages through the activation of cAMP/PKA, which results in the activation of AP-1. The treatment of macrophages with a PKA inhibitor or with antisense c-fos and c-jun oligonucleotides in the presence of PGE₂ prevented the increase of CD14 on the surface of these cells [107].

PGE₂ modulates a broad range of cytokines in peritoneal macrophages involved in inflammatory processes. Endogenous PGE₂ production in LPS-stimulated resident peritoneal macrophages acts as a brake for TNF-α and IL-12 synthesis [103]. The activation of peritoneal macrophages with other macrophage activators, such as IFN-γ and the fungal particle zymosan, induces the synthesis of cytokines, chemokines, lipid mediators, and reactive nitrogen and oxygen species that directly or indirectly modulate the synthesis of PGE₂. Of the mediators that modulate PGE₂ synthesis in these cells, NO seems to play a key role in inhibiting PGE₂ biosynthesis by nitrosylating and preventing the activity of COX-2 and mPGES [108].

The capacity of PGE₂ to modulate cytokine production clearly influences the inflammatory response during injury and infection. The susceptibility or resistance to infection in different mouse strains could be associated, at least in part, with the ability to stimulate the production of eicosanoids from phagocytes. When they are stimulated with LPS, peritoneal macrophages isolated from Balb/c mice produce approximately 3-fold more PGE₂ than the macrophages isolated from other mouse strains, such as C57BL. The higher levels of PGE₂ in the peritoneal macrophages of Balb/c mice are associated with high expression levels of sPLA₂ type V and mPGES mRNA relative to the levels in the macrophages of C57BL mice. The increased capacity to produce PGE₂ by the macrophages isolated from Balb/c mice directly reflects the inhibition of cytokines, such as IL-12 and TNF-α [109].

The peritoneal site also represents a primary organ to generate macrophage cell lines, which are very often used to study macrophage behavior and functions. Below we will highlight some of the key human and murine cell lines used to study PGE₂ production and actions.

### 8. RAW 264.7 Cells

RAW 264.7 cells are mouse macrophage-like cells established from the ascites of a tumor that was induced into a male Balb/c mouse by an intraperitoneal injection of Abelson leukemia virus (A-MuLV). These cells are extensively studied in models of inflammation, metabolism, and apoptosis, and they are used for in vitro drug screening. Currently, many reports have shown that EP₄ is the most abundant EP receptor in RAW 264.7 cells, followed by EP₂ and EP₃ but not EP₁ [110]. The expression of these receptors in RAW 246.7 cells can be modulated in a manner that is dependent on the inflammatory stimuli. TLR4 activation increases EP₂ and inhibits EP₄ receptor mRNA expression. In contrast, if these cells are stimulated only with IFN-γ, the expression of EP₂ and EP₄ decreases in a concentration-dependent manner [111].

Several inflammatory mediators, including TNF-α, IL-1 [112], and IFN-γ [113], can directly or indirectly increase the expression of COX-2 in RAW 246.7 cells. However, COX-2 expression and PGE₂ synthesis in IFN-γ-treated RAW 264.7 cells is directly regulated by TNF-α [114]. In the presence of an inflammatory stimulus, PGE₂ appears to have an autocrine effect in RAW 264.7 cells and can self-regulate the expression of COX-2. The pretreatment of cells with PGE₂ or EP₂/EP₄ agonists followed by the stimulation with LPS induced an increase in COX-2 expression, and this expression was completely inhibited in the presence of an adenyl cyclase inhibitor [115].

### 9. U937

U937 is a cell line isolated from the histiocytic lymphoma of a 37-year-old male and is used to study the differentiation of monocytes into mature macrophages in the presence of different stimuli, such as IFN-γ, phorbol 12-myristate 13-acetate (PMA), and vitamin D [116]. In PMA-differentiated cells, EP₄ is the predominant receptor, while only low levels of EP₁, EP₂, and EP₃ were detected [117]. Unstimulated U937s expressed high levels of EP2 on the surface; however, when these cells were incubated with different concentrations of PMA, the expression of EP₂ and the cAMP levels that were induced by PGE₂ decreased in a manner that was dependent on PKC [118].

Undifferentiated U937 cells produce low levels of PGE₂; however, in the presence of 12-0-tetradecanoylphorbol13-acetate (TPA), these cells produce high levels of PGE₂. U937 cells express high basal levels of PLA₂, cPLA₂, and iPLA₂β, and the presence of IFN-γ does not alter the expression of these proteins. The activation of these cells by the aggregation of FcyRI promotes the generation of PGE₂, but only iPLA₂β appears to be involved in the release of AA and the generation of this prostaglandin [119]. Untreated U937 cells or differentiated U937 cells in the presence of 1,25-dihydroxyvitamin D3 express only COX-1; however, when the differentiated cells are stimulated with serum-treated zymosan (STZ), they begin to express high levels of COX-2 in the presence of exogenous AA, they produce high levels of PGE₂ [120]. U937 cells differentiated in the presence of PMA express COX-2 and high levels of PGE₂, IL-1β, and TNF-α after 6 h of stimulation with LPS. However, unlike other cell types, the increased COX-2 levels in U937 cells are independent of the presence of IL-1β and TNF-α because the treatment of these cells with the respective neutralizing antibodies does not interfere with the expression of LPS-induced COX-2 [121].
10. Therapeutic Approaches

Because PGE\textsubscript{2} is the major PG product of most organs and its synthesis is upregulated during inflammatory conditions, which include infections and pathophysiologic conditions, it is expected that PGE\textsubscript{2} plays a nonredundant role in controlling the inflammatory response and modulating phagocyte function in diverse organs. Increased plasma PGE\textsubscript{2} levels have been reported in murine models and in patients who have undergone bone marrow transplantation [16, 122], are infected with HIV [123], display protein-calorie malnutrition [124], are smokers, are aging [125], or have cancer [126] or cystic fibrosis [127]. In all circumstances, these conditions are associated with susceptibility to infection. More specifically, in a murine bone marrow transplantation model, high levels of PGE\textsubscript{2} were observed in the lung and peritoneal lavage fluid, and the overproduction of PGE\textsubscript{2} by multiple cell types, including AMs, PMNs, and alveolar epithelial cells, was observed [16]. Similarly, a bactericidal PMN defect in guinea pigs following thermal burn injury has been linked to increased intracellular CAMP levels and the overproduction of PGE\textsubscript{2} [128]. In both a murine bone marrow transplant model and also a thermal burn injury, these defects were overcome by treatment with COX inhibitors. While COX inhibition is conventionally regarded to be an “anti-inflammatory” strategy, an alternative possibility is that COX inhibitors or other nonsteroidal anti-inflammatory drugs (NSAIDs) can prevent the overproduction of immunosuppressive PGE\textsubscript{2}, which may instead represent an “immunostimulatory” strategy. In contrast, in conditions in which PGE\textsubscript{2} exerts proinflammatory activities, such as in arthritis, atherosclerosis, and fever, COX inhibition is also an attractive target due to its analgesic and antipyretic properties. These drugs also have the beneficial effects of pathogen clearance. This effect has been shown that the in vivo treatment with NSAIDs enhances microbial clearance in different models of infection [26]. Although it has not been explicitly tested, we speculate that PGE\textsubscript{2} inhibition by NSAIDs should lead to reductions in intracellular CAMP levels, which may account for the immunostimulatory effects of NSAIDs in these models.

11. Conclusion

In summary, pharmacological inhibition or receptor genetic deletion in mice has unveiled the big diversity and distinct biological effects of PGE\textsubscript{2}. Depending on cell-specific signaling programs and the context of injury, EP receptors can mediate either bad or protective effects in processes that mediate various diseases. The development of highly selective pharmacological agents that targets individual EP receptors should be studied in clinical trials in different disease settings.

Authors’ Contribution

Alexandra Medeiros and Camila Peres-Buzalaf are equally contributed.

References

[1] S. L. Tilley, T. M. Coffman, and B. H. Koller, “Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes,” Journal of Clinical Investigation, vol. 108, no. 1, pp. 15–23, 2001.
[2] K. Subbaramaiah, W. J. Chung, and A. J. Dannenberg, “Ceramide regulates the transcription of cyclooxygenase-2: evidence for involvement of extracellular signal-regulated kinase/c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways,” Journal of Biological Chemistry, vol. 273, no. 49, pp. 32943–32949, 1998.
[3] M. M. Monick, P. K. Robeff, N. S. Butler et al., “Phosphatidylinositol 3-kinase activity negatively regulates stability of cyclooxygenase 2 mRNA,” Journal of Biological Chemistry, vol. 277, no. 36, pp. 32992–33000, 2002.
[4] P. I. Jakobsson, S. Thorén, R. Morgenstern, and B. Samuelsson, “Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 13, pp. 7220–7225, 1999.
[5] D. O. Stichtenoth, S. Thorén, H. Bian, M. Peters-Golden, P. I. Jakobsson, and L. J. Crofford, “Microsomal prostaglandin E synthase regulated by proinflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells,” The Journal of Immunology, vol. 167, no. 1, pp. 469–474, 2001.
[6] F. Kojima, H. Naraba, Y. Sasaki, R. Okamoto, T. Koshino, and S. Kawai, “Coexpression of microsomal prostaglandin E synthase with cyclooxygenase-2 in human rheumatoid synovial cells,” Journal of Rheumatology, vol. 29, no. 9, pp. 1836–1842, 2002.
[7] R. M. Breyer, C. K. Bagdassarian, S. A. Myers, and M. D. Breyer, “Prostanoid receptors: subtypes and signaling,” Annual Review of Pharmacology and Toxicology, vol. 41, pp. 661–690, 2001.
[8] A. F. Sheibanie, J. H. Yen, T. Khayrullina et al., “The proinflammatory effect of prostaglandin E\textsubscript{2} in experimental inflammatory bowel disease is mediated through the IL-23 → IL-17 axis,” The Journal of Immunology, vol. 178, no. 12, pp. 8138–8147, 2007.
[9] K. Takayama, G. K. Sukhova, M. T. Chin, and P. Libby, “A novel prostaglandin E receptor 4-associated protein participates in antiinflammatory signaling,” Circulation Research, vol. 98, no. 4, pp. 499–504, 2006.
[10] A. I. Medeiros, C. H. Serezani, S. P. Lee, and M. Peters-Golden, “Effecroticosis impairs pulmonary macrophage and lung antibacterial function via PGE\textsubscript{2}/EP2 signaling,” The Journal of Experimental Medicine, vol. 206, no. 1, pp. 61–68, 2009.
[11] C. N. Serhan, S. D. Brain, C. D. Buckley et al., “Resolution of inflammation: state of the art, definitions and terms,” The FASEB Journal, vol. 21, no. 2, pp. 325–332, 2007.
[12] R. Taha, R. Olivein, T. Utsumi et al., “Prostaglandin H synthase 2 expression in airway cells from patients with asthma and chronic obstructive pulmonary disease,” American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 2, pp. 636–640, 2000.
[13] S. L. Hempel, M. M. Monick, and G. W. Hunninghake, “Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes,” Journal of Clinical Investigation, vol. 93, no. 1, pp. 391–396, 1994.
[14] R. P. Charbeneau, P. J. Christensen, C. J. Chrisman et al., "Impaired synthesis of prostaglandin E2 by lung fibroblasts and alveolar epithelial cells from GM-CSF−/− mice: implications for fibroproliferation," *American Journal of Physiology Lung Cellular and Molecular Physiology*, vol. 284, no. 6, pp. L1103–L1111, 2003.

[15] B. B. Moore, M. J. Coffey, P. Christensen et al., "GM-CSF regulates bleomycin-induced pulmonary fibrosis via a prostaglandin-dependent mechanism," *The Journal of Immunology*, vol. 165, no. 7, pp. 4032–4039, 2000.

[16] M. N. Ballinger, D. M. Aronoff, T. R. McMillan et al., "Critical role of prostaglandin E2 overproduction in impaired pulmonary host response following bone marrow transplantation," *The Journal of Immunology*, vol. 177, no. 8, pp. 5499–5508, 2006.

[17] M. Profita, A. Sala, A. Bonanno et al., "Chronic obstructive pulmonary disease and neutrophil infiltration: role of cigarette smoke and cyclooxygenase products," *American Journal of Physiology—Lung Cellular and Molecular Physiology*, vol. 298, no. 2, pp. L261–L269, 2010.

[18] F. Herrmann, A. Lindemann, I. Gauss, and R. Mertelsmann, "Cytokine-stimulation of prostaglandin synthesis from endogenous and exogenous arachidonic acids in polymorphonuclear leukocytes involving activation and new synthesis of cyclooxygenase," *European Journal of Immunology*, vol. 20, no. 11, pp. 2513–2516, 1990.

[19] D. S. Whittaker, K. B. Bahjat, L. L. Moldawer, and M. J. Clare-Salzler, "Autoregulation of human monocye-derived dendritic cell maturation and IL-12 production by cyclooxygenase-2-mediated prostannoid production," *The Journal of Immunology*, vol. 165, no. 8, pp. 4298–4304, 2000.

[20] A. Lundequist, S. N. Nallamshetty, W. Xing et al., "Prostaglandin E2 exerts homeostatic regulation of pulmonary vascular remodeling in allergic airway inflammation," *The Journal of Immunology*, vol. 184, no. 1, pp. 433–441, 2010.

[21] S. G. Harris, J. Padilla, L. Koumas, D. Ray, and R. P. Phipps, "Prostaglandins as modulators of immunity," *Trends in Immunology*, vol. 23, no. 3, pp. 144–150, 2002.

[22] S. B. Gordon and R. C. Read, "Macrophage defences against respiratory tract infections," *British Medical Bulletin*, vol. 61, pp. 45–61, 2002.

[23] D. M. Aronoff, C. Canetti, and M. Peters-Golden, "Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP," *The Journal of Immunology*, vol. 173, no. 1, pp. 559–565, 2004.

[24] M. Monick, J. Glazier, and G. W. Hunninghake, "Human alveolar macrophages suppress interleukin-1 (IL-1) activity via the secretion of prostaglandin E2," *American Review of Respiratory Disease*, vol. 135, no. 1, pp. 72–77, 1987.

[25] Y. Sugimoto and S. Narumiya, "Prostaglandin E receptors," *Journal of Biological Chemistry*, vol. 282, no. 16, pp. 11613–11617, 2007.

[26] C. H. Sereznai, M. N. Ballinger, D. M. Aronoff, and M. Peters-Golden, "Cyclic AMP: master regulator of innate immune cell function," *American Journal of Respiratory Cell and Molecular Biology*, vol. 39, no. 2, pp. 127–132, 2008.

[27] G. Menard, V. Turmel, and E. Y. Bissonnette, "Serotonin modulates the cytokine network in the lung: Involvement of prostaglandin E2," *Clinical and Experimental Immunology*, vol. 150, no. 2, pp. 340–348, 2007.

[28] M. I. Ratchiffe, A. Walding, P. A. Shelton, A. Flaherty, and I. G. Dougall, "Activation of E-prostanoid 4 and E-prostanoid 2 receptors inhibits TNF-α release from human alveolar macrophages," *European Respiratory Journal*, vol. 29, no. 5, pp. 986–994, 2007.

[29] D. M. Aronoff, J. K. Carstens, G. H. Chen, G. B. Toews, and M. Peters-Golden, "Short communication: differences between macrophages and dendritic cells in the cyclic AMP-dependent regulation of lipopolysaccharide-induced cytokine and chemokine synthesis," *Journal of Interferon and Cytokine Research*, vol. 26, no. 11, pp. 827–833, 2006.

[30] S. H. Kim, C. H. Sereznai, K. Okunishi, Z. Zaslona, D. M. Aronoff, and M. Peters-Golden, "Distinct protein kinase A anchoring proteins direct prostaglandin E2 modulation of toll-like receptor signaling in alveolar macrophages," *Journal of Biological Chemistry*, vol. 286, no. 11, pp. 8875–8883, 2011.

[31] C. H. Sereznai, J. Chung, M. N. Ballinger, B. B. Moore, D. M. Aronoff, and M. Peters-Golden, "Prostaglandin E2 suppresses bacterial killing in alveolar macrophages by inhibiting NADPH oxidase," *American Journal of Respiratory Cell and Molecular Biology*, vol. 37, no. 5, pp. 562–570, 2007.

[32] C. Canetti, C. H. Sereznai, R. G. Atrasz, E. S. White, D. M. Aronoff, and M. Peters-Golden, "Activation of phosphatase and tension homolog on chromosome 10 mediates the inhibition of FcYR phagocytosis by prostaglandin E2 in alveolar macrophages," *The Journal of Immunology*, vol. 179, no. 12, pp. 8350–8356, 2007.

[33] D. M. Aronoff, C. Lewis, C. H. Sereznai et al., "E-prostanoid 3 receptor deletion improves pulmonary host defense and protects mice from death in severe Streptococcus pneumoniae infection," *The Journal of Immunology*, vol. 183, no. 4, pp. 2642–2649, 2009.

[34] B. W. Christman, J. W. Christman, R. Dworski, I. A. Blair, and C. Prakash, "Prostaglandin E2 limits arachidonic acid availability and inhibits leukotriene B4 synthesis in rat alveolar macrophages by a nonphospholipase A2 mechanism," *The Journal of Immunology*, vol. 151, no. 4, pp. 2096–2104, 1993.

[35] K. Sertl, T. Takemura, E. Tschachler, V. J. Ferrans, M. A. Kaliner, and E. M. Shevach, "Dendritic cells with antigen-presenting capability reside in airway epithelium, lung parenchyma, and visceral pleura," *The Journal of Experimental Medicine*, vol. 163, no. 2, pp. 436–451, 1986.

[36] E. Vassiliou, H. Jing, and D. Ganea, "Prostaglandin E2 inhibits TNF production in murine bone marrow-derived dendritic cells," *Cellular Immunology*, vol. 223, no. 2, pp. 120–132, 2003.

[37] M. Gonzalez-Juarreiro and I. M. Orme, "Characterization of murine lung dendritic cells infected with *Mycobacterium tuberculosis*," *Infection and Immunity*, vol. 69, no. 2, pp. 1127–1133, 2001.

[38] M. N. Ballinger, R. Paine III, C. H. C. Sereznai et al., "Role of granulocyte macrophage colony-stimulating factor during gram-negative lung infection with *Pseudomonas aeruginosa*," *American Journal of Respiratory Cell and Molecular Biology*, vol. 34, no. 6, pp. 766–774, 2006.

[39] A. Craig, J. Mai, S. Cai, and S. Jeyaseelan, "Neutrophil recruitment to the lungs during bacterial pneumonia," *Infection and Immunity*, vol. 77, no. 2, pp. 568–575, 2009.

[40] I. N. Mbwaike and H. B. Herscowitz, "MH-S, a murine anchoring proteins direct prostaglandin E2 modulation of toll-like receptor signaling in alveolar macrophages," *Journal of Immunology*, vol. 179, no. 12, pp. 8350–8356, 2007.

[41] M. Joo, Y. S. Hahn, M. Kwon, R. T. Sadikot, T. S. Blackwell, and J. W. Christman, "Hepatitis C virus core protein suppresses NF-κB activation and cyclooxygenase-2 expression by direct interaction with IκB kinase β," *Journal of Virology*, vol. 79, no. 12, pp. 7648–7657, 2005.
[42] C. Y. Chen, W. H. Peng, K. D. Tsai, and S. L. Hsu, “Luteolin suppresses inflammation-associated gene expression by blocking NF-κB and AP-1 activation pathway in mouse alveolar macrophages,” *Life Sciences*, vol. 81, no. 23–24, pp. 1602–1614, 2007.

[43] N. Gualde and H. Harizi, “Prostanoids and their receptors that modulate dendritic cell-mediated immunity,” *Immunology and Cell Biology*, vol. 82, no. 4, pp. 353–360, 2004.

[44] L. Boulet, M. Ouellet, K. P. Bateman et al., “Deletion of microsomal prostaglandin E2 (PGE2) synthase-1 reduces inducible and basal PGE2 production and alters the gastric prostanoid profile,” *Journal of Biological Chemistry*, vol. 279, no. 22, pp. 23229–23237, 2004.

[45] C. K. Ogle, J. D. Ogle, C. Johnson, L. Keynton, and J. W. Alexander, “The production of C3, PGE2, and TxB2 by splenic, alveolar, and peritoneal guinea pig macrophages,” *Prostaglandins*, vol. 36, no. 3, pp. 279–289, 1988.

[46] Y. Shibata, J. Gabbard, M. Yamashita et al., “Heat-killed BCG induces biphasic cyclooxygenase 2’ splenic macrophage formation—role of IL-10 and bone marrow precursors,” *Journal of Leukocyte Biology*, vol. 80, no. 3, pp. 590–598, 2006.

[47] Y. Shibata and A. Volkman, “The effect of bone marrow depletion on prostaglandin E-producing suppressor macrophages in mouse spleen,” *The Journal of Immunology*, vol. 155, no. 6, pp. 3897–3904, 1995.

[48] Y. Shibata, “Restoration of prostaglandin E2-producing splenic macrophages in 89Sr-treated mice with bone marrow from Corynebacterium parvum primed donors,” *Regional Immunology*, vol. 2, no. 3, pp. 169–175, 1989.

[49] N. Blyk and P. G. Holt, “Cytokine modulation of the immunosuppressive phenotype of pulmonary alveolar macrophage populations,” *Immunology*, vol. 86, no. 2, pp. 231–237, 1995.

[50] H. Harizi and N. Gualde, “Eicosanoids: an emerging role in dendritic cell biology,” *Archivum Immunologiae et Therapiae Experimentalis*, vol. 52, no. 1, pp. 1–5, 2004.

[51] H. Harizi, C. Grosset, and N. Gualde, “Prostaglandin E2 modulates dendritic cell function via EP2 and EP4 receptor subtypes,” *Journal of Leukocyte Biology*, vol. 73, no. 6, pp. 756–763, 2003.

[52] H. Harizi and N. Gualde, “Dendritic cells produce eicosanoids, which modulate generation and functions of antigen-presenting cells,” *Prostaglandins Leukotrienes and Essential Fatty Acids*, vol. 66, no. 5–6, pp. 459–466, 2002.

[53] Y. Shibata, A. Nishiyama, H. Ohata, J. Gabbard, Q. N. Myrvik, and R. A. Henriksen, “Differential effects of IL-10 on prostaglandin H synthase-2 expression and prostaglandin E2 biosynthesis between spleen and bone marrow macrophages,” *Journal of Leukocyte Biology*, vol. 77, no. 4, pp. 544–551, 2005.

[54] M. Betz and B. S. Fox, “Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines,” *The Journal of Immunology*, vol. 146, no. 1, pp. 108–113, 1991.

[55] K. K. Meja, P. J. Barnes, and M. A. Giembycz, “Characterization of the prostaglandin receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-α generation,” *British Journal of Pharmacology*, vol. 122, no. 1, pp. 149–157, 1997.

[56] H. P. Lemos, R. Grespan, S. M. Vieira et al., “Prostaglandin mediates IL-23/IL-17-induced neutrophil migration in inflammation by inhibiting IL-12 and IFNγ production,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 14, pp. 5954–5959, 2009.

[57] C. Chizzolini, R. Chicheportiche, M. Alvarez et al., “Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion,” *Blood*, vol. 112, no. 9, pp. 3696–3703, 2008.

[58] T. Suda, N. Takahashi, and T. J. Martin, “Modulation of osteoclast differentiation,” *Endocrine Reviews*, vol. 13, no. 1, pp. 66–80, 1992.

[59] Y. Kobayashi, I. Take, T. Yamashita et al., “Prostaglandin E2 receptors EP2 and EP4 are down-regulated during differentiation of mouse osteoclasts from their precursors,” *Journal of Biological Chemistry*, vol. 280, no. 25, pp. 24035–24042, 2005.

[60] K. J. Ibbotson, G. D. Roodman, L. M. McManus, and G. R. Mundy, “Identification and characterization of osteoclast-like cells and their progenitors in cultures of feline marrow mononuclear cells,” *Journal of Cell Biology*, vol. 99, no. 2, pp. 471–480, 1984.

[61] T. Suda, N. Takahashi, N. Udagawa, E. Jimi, M. T. Gillespie, and T. J. Martin, “Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families,” *Endocrine Reviews*, vol. 20, no. 3, pp. 345–357, 1999.

[62] Y. Y. Kong, H. Yoshida, I. Sarosi et al., “OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis,” *Nature*, vol. 397, no. 6717, pp. 315–323, 1999.

[63] S. Y. Han, N. K. Lee, K. H. Kim et al., “Transcriptional induction of cyclooxygenase-2 in osteoclast precursors is involved in RANKL-induced osteoclastogenesis,” *Blood*, vol. 106, no. 4, pp. 1240–1245, 2005.

[64] I. Suponitzky and M. Weinreb, “Differential effects of systemic prostaglandin E2 on bone mass in rat long bones and calvaria,” *Journal of Endocrinology*, vol. 156, no. 1, pp. 51–57, 1998.

[65] M. Mano, T. Arakawa, H. Mano et al., “Prostaglandin E2 directly inhibits bone-resorbing activity of isolated mature osteoclasts mainly through the EP4 receptor,” *Calcified Tissue International*, vol. 67, no. 1, pp. 85–92, 2000.

[66] T. Suzawa, C. Miyaura, M. Inada et al., “The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs,” *Endocrinology*, vol. 141, no. 4, pp. 1554–1559, 2000.

[67] F. González-Scarano and G. Baltuch, “Microglia as mediators of inflammatory and degenerative diseases,” *Annual Review of Neuroscience*, vol. 22, pp. 219–240, 1999.

[68] J. B. Leslie and W. D. Watkins, “Eicosanoids in the central nervous system,” *Journal of Neurosurgery*, vol. 63, no. 5, pp. 659–668, 1985.

[69] K. Yamagata, K. I. Andreasson, W. E. Kaufmann, C. A. Barnes, and P. F. Worley, “Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids,” *Neuron*, vol. 11, no. 2, pp. 371–386, 1993.

[70] N. V. Chandrasekharan, H. Dai, K. L. T. Roos et al., “COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 21, pp. 13926–13931, 2002.

[71] J. F. Dinchuk, R. Q. Liu, and J. M. Trzaskos, “COX-3: in the wrong frame in mind,” *Immunology Letters*, vol. 86, no. 1, p. 121, 2003.
[72] B. Kis, J. A. Snipes, T. Gaspar, G. Lenzser, C. D. Tulbert, and D. W. Busija, “Cloning of cyclooxygenase-1b (putative COX-3) in mouse,” Inflammation Research, vol. 55, no. 7, pp. 274–278, 2006.

[73] M. K. O’Banion, “Prostaglandin E2 synthases in neurologic homeostasis and disease,” Prostaglandins and Other Lipid Mediators, vol. 91, no. 3–4, pp. 113–117, 2010.

[74] A. Vazquez-Tello, L. Fan, X. Hou et al., “Intracellular-specific colocalization of prostaglandin E2 synthases and cyclooxygenases in the brain,” American Journal of Physiology—Regulatory and Comparative Physiology, vol. 287, no. 5, pp. R1155–R1163, 2004.

[75] A. Seregi, M. Keller, R. Jackisch, and G. Hertting, “Comparision of the prostanoid synthesizing capacity in homogenates from primary neuronal and astroglial cell cultures,” Biochemical Pharmacology, vol. 33, no. 20, pp. 3315–3318, 1984.

[76] L. Minghetti and G. Levi, “Induction of prostanoid biosynthesis by bacterial lipopolysaccharide and iso-proterenol in rat microglial cultures,” Journal of Neurochemistry, vol. 65, no. 6, pp. 2690–2698, 1995.

[77] L. Minghetti and G. Levi, “Microglia as effector cells in brain damage and repair: focus on prostanooids and nitric oxide,” Progress in Neurobiology, vol. 54, no. 1, pp. 99–125, 1998.

[78] Y. Ikeda-Matsuo, Y. Ikegaya, N. Matsuki, S. Uematsu, S. Akira, and Y. Sasaki, “Microglia-specific expression of microsomal prostaglandin E2 synthase-1 contributes to lipopolysaccharide-induced prostaglandin E2 production,” Journal of Neurochemistry, vol. 94, no. 6, pp. 1546–1558, 2005.

[79] L. Minghetti, E. Polazzi, A. Nicolini, and G. Levi, “Opposite regulation of prostaglandin E2 synthesis by transforming growth factor-b1 and interleukin 10 in activated microglial cultures,” Journal of Neuroimmunology, vol. 82, no. 1, pp. 31–39, 1998.

[80] G. Levi, L. Minghetti, and F. Aloisi, “Regulation of prostanoid synthesis in microglial cells and effects of prostaglandin E2 on microglial functions,” Biochimie, vol. 80, no. 11, pp. 899–904, 1998.

[81] J. C. M. Schlachetzki, B. L. Fiebich, E. Haake et al., “Norepinephrine enhances the LPS-induced expression of COX-2 and secretion of PGE2 in primary rat microglia,” Journal of Neuroinflammation, vol. 7, article 2, 2010.

[82] L. Minghetti, E. Polazzi, A. Nicolini, C. Creminon, and G. Levi, “Up-regulation of cyclooxygenase-2 expression in cultured microglia by prostaglandin E2, cyclic AMP and non-steroidal anti-inflammatory drugs,” European Journal of Neuroscience, vol. 9, no. 5, pp. 934–940, 1997.

[83] L. Minghetti, E. Polazzi, A. Nicolini, C. Creminon, and G. Levi, “Interferon-g and nitric oxide down-regulate lipopolysaccharide-induced prostanooid production in cultured rat microglial cells by inhibiting cyclooxygenase-2 expression,” Journal of Neurochemistry, vol. 66, no. 5, pp. 1953–1970, 1996.

[84] L. Minghetti, A. Nicolini, E. Polazzi et al., “Down-regulation of microglial cyclo-oxygenase-2 and inducible nitric oxide synthase expression by lipocartin 1,” British Journal of Pharmacology, vol. 126, no. 6, pp. 1307–1314, 1999.

[85] J. Zhang, S. Fujii, Z. Wu et al., “Involvement of COX-1 and up-regulated prostaglandin e synthases in phosphatidylinerine liposome-induced prostaglandin E2 production by microglia,” Journal of Neuroimmunology, vol. 172, no. 1-2, pp. 112–120, 2006.

[86] F. Aloisi, R. de Simone, S. Columba-Cabez, and G. Levi, “Opposite effects of interferon-gamma and prostaglandin E2 on tumor necrosis factor and interleukin-10 production in microglia: a regulatory loop controlling microglia pro- and anti-inflammatory activities,” Journal of Neuroscience Research, vol. 56, no. 6, pp. 571–580.

[87] F. Aloisi, G. Penna, J. Cerese, B. Menendez Iglesias, and L. Adorini, “IL-12 production by central nervous system microglia is inhibited by astrocytes,” The Journal of Immunology, vol. 159, no. 4, pp. 1604–1612, 1997.

[88] K. Suk, S. You Kim, and H. Kim, “Regulation of IL-18 production by IFNγ and PGE2 in mouse microglial cells: involvement of NF-kB pathway in the regulatory processes,” Immunology Letters, vol. 77, no. 2, pp. 79–85, 2001.

[89] B. M. Iglesias, J. Cerese, C. Ceracchini, G. Levi, and F. Aloisi, “Analysis of B7-1 and B7-2 costimulatory ligands in cultured mouse microglia: upregulation by interferon-γ and lipopolysaccharide and downregulation by interleukin-10, prostaglandin E2 and cyclic AMP-elevating agents,” Journal of Neuroimmunology, vol. 72, no. 1, pp. 83–93, 1997.

[90] R. Mittal, I. Gonzalez-Gomez, A. Panigrahy, K. Goth, R. Bonnet, and N. V. Prasadarsao, “IL-10 administration reduces PGE2 levels and promotes CR3-mediated clearance of Escherichia coli K1 by phagocytes in menigitis,” The Journal of Experimental Medicine, vol. 207, no. 6, pp. 1307–1319, 2010.

[91] S. Rivest, “What is the cellular source of prostaglandins in the brain in response to systemic inflammation? Facts and controversies,” Molecular Psychiatry, vol. 4, no. 6, pp. 501–507, 1999.

[92] A. Nadjar, J. Sauvant, C. Combe, P. Parnet, and J. P. Konsman, “Brain cyclooxygenase-2 mediates interleukin-1-induced cellular activation in preoptic and arcuate hypothalamus, but not sickness symptoms,” Neurobiology of Disease, vol. 39, no. 3, pp. 393–401, 2010.

[93] J. Guay, K. Bateman, R. Gordon, J. Mancini, and D. Rendeau, “Carrageenan-induced paw edema in rat elicits a predominant prostaglandin E2 (PGE2) response in the central nervous system associated with the induction of microsomal PGE2 synthase-1,” Journal of Biological Chemistry, vol. 279, no. 23, pp. 24866–24872, 2004.

[94] H. Yang and C. Chen, “Cyclooxygenase-2 in synaptic signaling,” Current Pharmaceutical Design, vol. 14, no. 14, pp. 1443–1451, 2008.

[95] D. Milatovic, T. J. Montine, and M. Aschner, “Prostanoid signaling: dual role for prostaglandin E2 in neurotoxicity,” NeuroToxicology, vol. 32, no. 3, pp. 312–319, 2011.

[96] K. Andreasson, “Emerging roles of PGE2 receptors in models of neurological disease,” Prostaglandins and Other Lipid Mediators, vol. 91, no. 3–4, pp. 104–112, 2010.

[97] F. Shie, K. S. Montine, R. M. Breyer, and T. J. Montine, “Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity,” GLIA, vol. 52, no. 1, pp. 70–77, 2005.

[98] J. Shi, J. Johansson, N. S. Woodling, Q. Wang, T. J. Montine, and K. Andreasson, “The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity,” The Journal of Immunology, vol. 184, no. 12, pp. 7207–7218, 2010.

[99] T. Nagamatsu and D. J. Schust, “Review: the immunomodulatory roles of macrophages at the maternal-fetal interface,” Reproductive Sciences, vol. 17, no. 3, pp. 209–218, 2010.
R. Ikegami, Y. Sugimoto, E. Segi et al., “The expression of prostaglandin E receptors EP2 and EP4 and their different regulation by lipopolysaccharide in C3H/HeN peritoneal macrophages,” The Journal of Immunology, vol. 166, no. 7, pp. 4689–4696, 2001.

J. Wilborn, D. L. DeWitt, and M. Peters-Golden, “Expression regulation by lipopolysaccharide in C3H/HeN peritoneal macrophages,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 268, no. 2, pp. L294–L301, 1995.

G. Strassmann, V. Patil-Koota, F. Finkelman, M. Fong, and T. Kambayashi, “Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2,” The Journal of Experimental Medicine, vol. 180, no. 6, pp. 2365–2370, 1994.

I. Wakahara, S. Hanawat, and S. Hata, “Expression of prostaglandin E receptors EP2 and EP4 and their differential regulation by lipopolysaccharide in C3H/HeN peritoneal macrophages,” The Journal of Immunology, vol. 164, no. 10, pp. 5403–5408, 2000.

E. Kuroda and U. Yamashita, “Mechanisms of enhanced macrophage-mediated prostaglandin E2 production and its suppressive role in Th1 activation in Th2-dominant BALB/c mice,” The Journal of Immunology, vol. 170, no. 2, pp. 757–764, 2003.

T. Tajima, T. Murata, K. Aritake et al., “Lipopolysaccharide induces macrophage migration via prostaglandin D2 and prostaglandin E2,” Journal of Pharmacology and Experimental Therapeutics, vol. 326, no. 2, pp. 493–501, 2008.

E. Kuroda and U. Yamashita, “Mechanisms of enhanced macrophage-mediated prostaglandin E2 production and its suppressive role in Th1 activation in Th2-dominant BALB/c mice,” The Journal of Immunology, vol. 170, no. 2, pp. 757–764, 2003.
[128] A. B. Bjornson, R. W. Knippenberg, and H. S. Bjornson, "Nonsteroidal anti-inflammatory drugs correct the bactericidal defect of polymorphonuclear leukocytes in a guinea pig model of thermal injury," *Journal of Infectious Diseases*, vol. 157, no. 5, pp. 959–967, 1988.